Analysts Set Scholar Rock Holding Corporation (NASDAQ:SRRK) Target Price at $45.75

Key Points

• Scholar Rock Holding Corporation (NASDAQ:SRRK) has received a consensus rating of "Buy" from ten analysts, with an average twelve-month price target of $45.75.
• Insider trading activity includes a significant sale by Director Jeffrey S. Flier, who sold over 20,000 shares, resulting in a 45.77% decrease in his position.
• Scholar Rock reported a net loss of $0.98 EPS for the last quarter, missing analysts' expectations, while also working on promising therapies like Apitegromab for spinal muscular atrophy.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) has earned a consensus recommendation of "Buy" from the ten brokerages that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $45.75.

Several research firms recently commented on SRRK. Cantor Fitzgerald began coverage on Scholar Rock in a research note on Thursday, July 17th. They issued an "overweight" rating on the stock. BMO Capital Markets dropped their price objective on Scholar Rock from $57.00 to $45.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. Jefferies Financial Group started coverage on Scholar Rock in a research report on Thursday, August 21st. They set a "buy" rating and a $50.00 target price on the stock. Lifesci Capital upgraded Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Finally, Raymond James Financial set a $53.00 target price on Scholar Rock and gave the stock a "strong-buy" rating in a research report on Wednesday, July 30th.

Scholar Rock Stock Performance

Scholar Rock stock traded down $1.03 during trading on Thursday, hitting $31.41. The stock had a trading volume of 2,113,953 shares, compared to its average volume of 1,712,805. Scholar Rock has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.21. The stock's 50 day moving average is $35.46 and its two-hundred day moving average is $33.49. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -10.79 and a beta of 0.36.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same quarter last year, the firm posted ($0.60) earnings per share. As a group, analysts predict that Scholar Rock will post -2.42 EPS for the current year.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, Director Jeffrey S. Flier sold 11,136 shares of the stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $40.02, for a total transaction of $445,662.72. Following the sale, the director owned 24,070 shares in the company, valued at $963,281.40. This represents a 31.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mo Qatanani sold 24,066 shares of the stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total value of $828,833.04. Following the sale, the insider owned 115,495 shares in the company, valued at approximately $3,977,647.80. This represents a 17.24% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,654 shares of company stock worth $2,299,310. Company insiders own 13.30% of the company's stock.

Institutional Investors Weigh In On Scholar Rock

Institutional investors and hedge funds have recently made changes to their positions in the business. Lord Abbett & CO. LLC raised its position in shares of Scholar Rock by 86.2% in the first quarter. Lord Abbett & CO. LLC now owns 877,374 shares of the company's stock worth $28,207,000 after buying an additional 406,074 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Scholar Rock by 42.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company's stock worth $5,845,000 after buying an additional 40,436 shares in the last quarter. Northern Trust Corp raised its position in shares of Scholar Rock by 2.5% in the first quarter. Northern Trust Corp now owns 765,280 shares of the company's stock worth $24,604,000 after buying an additional 18,753 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Scholar Rock by 3,824.9% in the first quarter. GAMMA Investing LLC now owns 30,928 shares of the company's stock worth $962,000 after buying an additional 30,140 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Scholar Rock in the first quarter worth $12,775,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.